Imlunestrant vs Vepdegestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Imlunestrant · Inluriyo
Marketed by Eli Lilly
NCT04975308 · Phase 3 · active, not recruiting
EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.
Next expected readout: October 2028 · NCT07905001 (registry estimate)
Reported efficacy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)
Result source: NCT04975308
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Imlunestrant | Vepdegestrant |
|---|---|---|
| PFS, median | 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT049753087 other results
| 3.7 vs 3.6vs FulvestrantNCT056546231 other result
|
| OS, median | —Trial running · NCT04975308 | —Trial running · NCT05909397 |
| ORR | 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
| 10.9% vs 3.6%vs FulvestrantNCT05654623 |
| Clinical benefit rate | 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT049753083 other results
| 34.3% vs 28.7%vs FulvestrantNCT05654623 |
PFS, median
- Imlunestrant
- 5.5 vs 5.5vs Investigator's Choice of Endocrine TherapyNCT04975308
7 other results
- 5.5 vs 3.8 NCT04975308
- 9.4 NCT04975308
- 5.5 NCT04975308
- 9.2 vs 7.4 NCT04975308
- 7.4 vs 5.5 NCT04975308
- 14.5 NCT04975308
- 9.2 NCT04975308
- Vepdegestrant
- 3.7 vs 3.6vs FulvestrantNCT05654623
1 other result
- 5 vs 2.1 NCT05654623
OS, median
- Imlunestrant
- —Trial running · NCT04975308
- Vepdegestrant
- —Trial running · NCT05909397
ORR
- Imlunestrant
- 10.3% vs 6.4%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 11.6% vs 5.9% NCT04975308
- 21.1% NCT04975308
- 9.4% NCT04975308
- Vepdegestrant
- 10.9% vs 3.6%vs FulvestrantNCT05654623
Clinical benefit rate
- Imlunestrant
- 46.8% vs 45.5%vs Investigator's Choice of Endocrine TherapyNCT04975308
3 other results
- 46.4% vs 36.4% NCT04975308
- 62.9% NCT04975308
- 44.1% NCT04975308
- Vepdegestrant
- 34.3% vs 28.7%vs FulvestrantNCT05654623
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Imlunestrant: 5 of 5 rows · Vepdegestrant: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Imlunestrant | Vepdegestrant |
|---|---|---|
| Duration of Response time to event · months | 11.1 vs 7.39 Investigator's Choice of Endocrine Therapy monthsa,b NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose10.02 vs 5.59 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | NA vs 7.4 Fulvestrant monthsb NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Dropout rate | 25.7%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result45.1%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 7.8%c NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result5.6%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | —c NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 14.1%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result20.2%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 4%c NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | diarrhoea 21.7% nausea 18% arthralgia 15.3% NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more resultdiarrhoea 86.5% nausea 50% anaemia 43.8% NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | c hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bThe assessment timepoint is not available for both results.
- cPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Imlunestrant
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Vepdegestrant
Breast Cancer
Shared mechanism: Estrogen receptor · full Breast Cancer pipeline
Imlunestrant · Inluriyo
Marketed by Eli Lilly
NCT04975308 · Phase 3 · active, not recruiting
EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.
Next expected readout: October 2027 · NCT05514054 (registry estimate)
Reported efficacy
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)
Result source: NCT04975308
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Imlunestrant: 8 of 8 rows · Vepdegestrant: 7 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Imlunestrant | Vepdegestrant |
|---|---|---|
| Clinical Benefit responder rate · % of participants | 46.8% (n=331) vs 45.5% (n=330) Investigator's Choice of Endocrine Therapya,b NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose46.4% (n=138) vs 36.4% (n=118) Investigator's Choice of Endocrine Therapy NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 34.3% (n=274) vs 28.7% (n=272) Fulvestrantb NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Duration of Response time to event · months | 11.1 vs 7.39 Investigator's Choice of Endocrine Therapy monthsa,b NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose10.02 vs 5.59 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | NA vs 7.4 Fulvestrant monthsb NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| ORR responder rate · % of participants | 10.3% (n=331) vs 6.4% (n=330) Investigator's Choice of Endocrine Therapya,b NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose11.6% (n=138) vs 5.9% (n=118) Investigator's Choice of Endocrine Therapy NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 10.9% (n=221) vs 3.6% (n=222) Fulvestrantb NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| PFS time to event · months | 5.55 vs 5.52 Investigator's Choice of Endocrine Therapy monthsa,b NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 3 more doses5.49 vs 3.84 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9.23 vs 7.36 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7.43 vs 5.49 Investigator's Choice of Endocrine Therapy months NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 3.7 vs 3.6 Fulvestrant monthsa,b NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose5 vs 2.1 Fulvestrant months NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Dropout rate | 25.7%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result45.1%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 7.8%c NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result5.6%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | —c NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 14.1%Arm A: Imlunestrant NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result20.2%Arm C: Imlunestrant + Abemaciclib NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 4%c NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | diarrhoea 21.7% nausea 18% arthralgia 15.3% NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more resultdiarrhoea 86.5% nausea 50% anaemia 43.8% NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | c hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bThe assessment timepoint is not available for both results.
- cPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Imlunestrant
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Vepdegestrant
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Imlunestrant's landscape · Vepdegestrant's landscape